{"title":"COVID-19患者肺炎支原体合并感染的患病率:一项系统综述","authors":"H. Akbari","doi":"10.22037/AMLS.V6.32399","DOIUrl":null,"url":null,"abstract":"COVID-19 pneumonia signs and symptoms are not specific and it may be similar to other cases of pneumonia caused by other microorganisms such as Mycoplasma pneumonia. This study aimed to investigate the prevalence of M. pneumonia co-infection among patients with COVID-19 by a systematic review and meta-analysis. \nTwo authors performed the search process independently in Scopus, Web of sciences, and PubMed for studies reporting COVID-19-associated Mycoplasma pneumonia co-infections published in the English language from December 2019 to 1st June 2020. The MeSH terms used in the present review were; “COVID-19”, “co-infection”, “secondary infection”, “2019 novel coronavirus”, “2019-nCoV”, “COVID-19 virus”, “coronavirus disease 2019 virus”, “Mycoplasma pneumoniae”, “M. pneumoniae”, “prevalence”, and “respiratory pathogens”. Data analyzed using Comprehensive Meta-analysis (CMA) software. Heterogeneity among included studies was checked by I2 statistic and the Q2 test. M. pneumonia co-infection was varied between 1 and 40.6% in the included studies. The combined prevalence of M. pneumoniae co-infection among patients with COVID-19 was reported by 17% (95% CI: 7.4–34.3). \nOverall, our systematic review and meta-analysis showed a quite high co-infection of M. pneumonia in patients with COVID-19 infection, therefore, routine diagnostic tests are recommended for respiratory pathogens like M. pneumonia, because on-time treatment has a beneficial effect on patient survival. Also, an increasing number of cases of asymptomatic COVID-19 infection, the differentiation and diagnosis of pneumonia caused by COVID-19 from non-COVID-19 pneumonia be considered. It helps avoid unnecessary quarantine and waste of medical resources. \n*Corresponding Author: Hakimeh Akbari; Email: akbarih@gerums.ac.ir \nPlease cite this article as: Akbari H. Prevalence of Mycoplasma pneumonia Coinfection among Patients with COVID-19; a systematic review. Arch Med Lab Sci. 2020;6:e3. https://doi.org/10.22037/amls.v6.32399","PeriodicalId":18401,"journal":{"name":"Medical laboratory sciences","volume":"52 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence of Mycoplasma pneumonia Coinfection among Patients with COVID-19: A Systematic Review\",\"authors\":\"H. Akbari\",\"doi\":\"10.22037/AMLS.V6.32399\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"COVID-19 pneumonia signs and symptoms are not specific and it may be similar to other cases of pneumonia caused by other microorganisms such as Mycoplasma pneumonia. This study aimed to investigate the prevalence of M. pneumonia co-infection among patients with COVID-19 by a systematic review and meta-analysis. \\nTwo authors performed the search process independently in Scopus, Web of sciences, and PubMed for studies reporting COVID-19-associated Mycoplasma pneumonia co-infections published in the English language from December 2019 to 1st June 2020. The MeSH terms used in the present review were; “COVID-19”, “co-infection”, “secondary infection”, “2019 novel coronavirus”, “2019-nCoV”, “COVID-19 virus”, “coronavirus disease 2019 virus”, “Mycoplasma pneumoniae”, “M. pneumoniae”, “prevalence”, and “respiratory pathogens”. Data analyzed using Comprehensive Meta-analysis (CMA) software. Heterogeneity among included studies was checked by I2 statistic and the Q2 test. M. pneumonia co-infection was varied between 1 and 40.6% in the included studies. The combined prevalence of M. pneumoniae co-infection among patients with COVID-19 was reported by 17% (95% CI: 7.4–34.3). \\nOverall, our systematic review and meta-analysis showed a quite high co-infection of M. pneumonia in patients with COVID-19 infection, therefore, routine diagnostic tests are recommended for respiratory pathogens like M. pneumonia, because on-time treatment has a beneficial effect on patient survival. Also, an increasing number of cases of asymptomatic COVID-19 infection, the differentiation and diagnosis of pneumonia caused by COVID-19 from non-COVID-19 pneumonia be considered. It helps avoid unnecessary quarantine and waste of medical resources. \\n*Corresponding Author: Hakimeh Akbari; Email: akbarih@gerums.ac.ir \\nPlease cite this article as: Akbari H. Prevalence of Mycoplasma pneumonia Coinfection among Patients with COVID-19; a systematic review. Arch Med Lab Sci. 2020;6:e3. https://doi.org/10.22037/amls.v6.32399\",\"PeriodicalId\":18401,\"journal\":{\"name\":\"Medical laboratory sciences\",\"volume\":\"52 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical laboratory sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22037/AMLS.V6.32399\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical laboratory sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22037/AMLS.V6.32399","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
COVID-19肺炎的体征和症状不具有特异性,可能与其他微生物(如肺炎支原体)引起的其他肺炎病例相似。本研究旨在通过系统回顾和荟萃分析调查COVID-19患者中肺炎支原体合并感染的患病率。两位作者在Scopus、Web of sciences和PubMed中独立进行了搜索过程,检索了2019年12月至2020年6月1日以英语发表的报告covid -19相关支原体肺炎合并感染的研究。本审查中使用的MeSH术语是;“COVID-19”、“合并感染”、“继发感染”、“2019新型冠状病毒”、“2019- ncov”、“COVID-19病毒”、“冠状病毒病2019病毒”、“肺炎支原体”、“M。“肺炎”、“患病率”和“呼吸道病原体”。数据分析采用综合元分析(CMA)软件。采用I2统计量和Q2检验检验纳入研究间的异质性。在纳入的研究中,肺炎支原体合并感染的发生率在1%至40.6%之间。COVID-19患者中合并肺炎支原体感染的总患病率为17% (95% CI: 7.4-34.3)。总体而言,我们的系统回顾和荟萃分析显示,COVID-19感染患者的肺炎支原体合并感染率相当高,因此,建议对肺炎支原体等呼吸道病原体进行常规诊断检查,因为及时治疗对患者的生存有有益的影响。同时,随着新冠肺炎无症状感染者的增多,需要考虑新冠肺炎与非新冠肺炎的鉴别诊断。这有助于避免不必要的隔离和医疗资源的浪费。*通讯作者:Hakimeh Akbari;Akbari H. COVID-19患者肺炎支原体合并感染的患病率;系统回顾。中华医学杂志,2020;6:3。https://doi.org/10.22037/amls.v6.32399
Prevalence of Mycoplasma pneumonia Coinfection among Patients with COVID-19: A Systematic Review
COVID-19 pneumonia signs and symptoms are not specific and it may be similar to other cases of pneumonia caused by other microorganisms such as Mycoplasma pneumonia. This study aimed to investigate the prevalence of M. pneumonia co-infection among patients with COVID-19 by a systematic review and meta-analysis.
Two authors performed the search process independently in Scopus, Web of sciences, and PubMed for studies reporting COVID-19-associated Mycoplasma pneumonia co-infections published in the English language from December 2019 to 1st June 2020. The MeSH terms used in the present review were; “COVID-19”, “co-infection”, “secondary infection”, “2019 novel coronavirus”, “2019-nCoV”, “COVID-19 virus”, “coronavirus disease 2019 virus”, “Mycoplasma pneumoniae”, “M. pneumoniae”, “prevalence”, and “respiratory pathogens”. Data analyzed using Comprehensive Meta-analysis (CMA) software. Heterogeneity among included studies was checked by I2 statistic and the Q2 test. M. pneumonia co-infection was varied between 1 and 40.6% in the included studies. The combined prevalence of M. pneumoniae co-infection among patients with COVID-19 was reported by 17% (95% CI: 7.4–34.3).
Overall, our systematic review and meta-analysis showed a quite high co-infection of M. pneumonia in patients with COVID-19 infection, therefore, routine diagnostic tests are recommended for respiratory pathogens like M. pneumonia, because on-time treatment has a beneficial effect on patient survival. Also, an increasing number of cases of asymptomatic COVID-19 infection, the differentiation and diagnosis of pneumonia caused by COVID-19 from non-COVID-19 pneumonia be considered. It helps avoid unnecessary quarantine and waste of medical resources.
*Corresponding Author: Hakimeh Akbari; Email: akbarih@gerums.ac.ir
Please cite this article as: Akbari H. Prevalence of Mycoplasma pneumonia Coinfection among Patients with COVID-19; a systematic review. Arch Med Lab Sci. 2020;6:e3. https://doi.org/10.22037/amls.v6.32399